Search Within

Advanced Practice Providers

  1. "Solid Tumor Oncology Division"
Formats
  1. Meeting Abstract (192)
  2. Journal Article (122)
  3. Research Letter (3)
  4. Review (3)
  5. Editorial (2)
  6. Book Section (1)
  7. Miscellaneous (1)
Groups
  1. Solid Tumor Oncology Division (324)
  2. Department of Medicine (323)
  3. Nursing (271)
  4. Survivorship Research (152)
  5. Gastrointestinal Oncology Service (137)
  6. Epidemiology and Biostatistics (123)

More Groups

People
  1. Ellen Hollywood (37)
  2. Leonard Saltz (31)
  3. Armin Shahrokni (30)
  4. Diane Reidy (28)
  5. Andrew Epstein (27)
  6. Beatriz Korc-Grodzicki (27)

More People

Years
  1. 2025 (8)
  2. 2024 (22)
  3. 2023 (16)
  4. 2022 (22)
  5. 2021 (23)
  6. 2020 (23)

More Years

Publications
  1. Journal of Clinical Oncology (116)
  2. Blood (11)
  3. Cancer (11)
  4. Cancer Research (9)
  5. Clinical Cancer Research (9)
  6. Journal of Pain and Symptom Management (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (132)
  2. Elsevier Inc. (36)
  3. American Association for Cancer Research (27)
  4. Wiley Blackwell (22)
  5. Oxford University Press (15)
  6. American Society of Hematology (12)

More Publishers

Results (324)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: Results from Phase 2
    Meeting Abstract

    Rizvi, N. A.; Kris, M. G.; Miller, V. A.; Krug, L. M.; Bekele, S.; Dowlati, A.; Rowland, K. M.; Salgia, R.; Aggarwal, N.; Gadgeel, S. M.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
    Journal Article

    Yuan, J.; Gnjatic, S.; Li, H.; Powel, S.; Gallardo, H. F.; Ritter, E.; Ku, G. Y.; Jungbluth, A. A.; Segal, N. H.; Rasalan, T. S.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2008)

    Fulltext@MSK | Save
  • A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors
    Journal Article

    Tse, A. N.; Klimstra, D. S.; Gonen, M.; Shah, M.; Sheikh, T.; Sikorski, R.; Carvajal, R.; Mui, J.; Tipian, C.; O'reilly, E.; more...
    Clinical Cancer Research (2008)

    Fulltext@MSK | Save
  • Changing indications for surgery in patients with stage IV breast cancer: A current perspective
    Journal Article

    Morrogh, M.; Park, A.; Norton, L.; King, T. A.
    Cancer (2008)

    Fulltext@MSK | Save
  • The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor
    Journal Article

    Holen, K.; Saltz, L. B.; Hollywood, E.; Burk, K.; Hanauske, A. R.
    Investigational New Drugs (2008)

    Fulltext@MSK | Save
  • Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer
    Meeting Abstract

    Zhang, W.; Yang, D.; Capanu, M.; Hollywood, E.; Lue-Yat, M.; Borucka, E.; Azuma, M.; Gordon, M.; Saltz, L.; Lenz, H.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Bevacizumab 5mg/kg can be safely infused over 10 minutes
    Meeting Abstract

    Reidy, D. L.; Chung, K. Y.; Timoney, J. P.; Park, V.; Hollywood, E.; Sklarin, N.; Muller, R.; Saltz, L.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Molecular markers associated with response and clinical outcome to cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer (BOND2)
    Meeting Abstract

    Azuma, M.; Yang, D.; Carpanu, M.; Hollywood, E.; Lue-Yat, M.; Zhang, W.; Danenberg, K. D.; Danenberg, P. V.; Saltz, L.; Lenz, H.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Phase I study of the antifolate pralatrexate given with vitamin B(12) and folic acid supplementation in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Azzoli, C. G.; Krug, L.; Miller, V.; Bekele, S.; Tyson, L.; Dunne, M.; Huntington, M.; Saunders, M.; Kris, M. G.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • A phase II study of XL647 in patients with non-small cell lung cancer (NSCLC) enriched for presence of EGFR mutations
    Meeting Abstract

    Rizvi, N.; Kris, M.; Miller, V.; Krug, L.; Bekele, S.; Dowlati, A.; Rowland, K.; Tonda, M.; Mitchell, B.; Ruckdeschels, J.; more...
    Molecular Cancer Therapeutics (2007)

    Fulltext@MSK | Save